RVMD
Revolution Medicines Inc (RVMD)
Healthcare • NASDAQ • $169.77+0.15%
- Symbol
- RVMD
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $169.77
- Daily Change
- +0.15%
- Market Cap
- $34.65B
- Trailing P/E
- N/A
- Forward P/E
- -28.58
- 52W High
- $166.50
- 52W Low
- $34.00
- Analyst Target
- $187.29
- Dividend Yield
- N/A
- Beta
- 1.41
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients…
Company websiteResearch RVMD on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.